Renal Biomarkers Technologies and Global Report 2022: Market Data and Projections 2019-2027 Featuring BioMerieux, Gentian Diagnostic, Proteomics, Thermo Fisher Scientific, SphingoTec, and BioPorto – Yahoo Finance
DUBLIN, Jan. 4, 2023 /PRNewswire/ — The “Renal Biomarkers: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering.
This report incorporates an in-depth analysis of the renal biomarker market, including market estimations and trends through 2021.
Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the CAGR for renal biomarkers.
The renal biomarker market is growing at a steady pace due the increasing prevalence and incidence of the two major kidney diseases: acute kidney injury (AKI) and chronic kidney disease (CKD). These diseases increase hospitalization time, leading to higher costs and morbidity. Early identification of such diseases leads to better treatment, which is possible through biomarkers.
COVID-19 has had a huge impact in increasing the incidence of kidney diseases. Long-term COVID patients have a higher incidence of AKI or CKD. The prevalence of lifestyle diseases such as diabetes and hypertension is also rising. These are closely associated with kidney disorders and malfunction. These diseases are currently the 16th leading cause of death but are expected to be fifth leading by 2030.
The traditional biomarkers used for detecting AKI and CKD have many disadvantages compared to new and novel biomarkers. New biomarkers are being studied and discovered, as there is a gap for an ideal renal biomarker. There is no single renal tumor biomarker that can be pursued by the industry.
The scope of the report extends only to renal biomarker consumables and not devices used to study renal biomarkers. All types of renal biomarkers have been considered in research, clinical trials and for diagnostic purposes.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World (RoW) region. For market estimates, data is provided for 2021 as the base year, 2022 and forecast through year-end 2027.
Report Includes
Analyses of the global market trends, with market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Estimation of the actual market size and revenue forecast for renal biomarkers market, and corresponding market share analysis by assay type, application, end user, and region
Updated information on market drivers and opportunities for renal biomarkers, key shifts, regulations and industry specific challenges, and other demographic factors that will shape the market demand over the coming years (2022-2027)
Identification of the companies best positioned to meet the demand owing to their proprietary technologies, product launches, mergers and acquisitions, and other market strategic advantages
Review of recent industry structure for biomarkers, R&D activities, and analysis of the competitive landscape based on recent developments and segmental revenues
Patent activity and review of patent grants for biomarkers and related technologies
Descriptive company profiles of the market leading players, including BioMerieux, Gentian Diagnostic, Proteomics International, Thermo Fisher Scientific, SphingoTec, and BioPorto
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
3.1 Introduction
3.1.1 Kidneys
3.1.2 Renal Biomarkers
3.1.3 Definition
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.3 Regulatory Process for Biomarkers
3.3.1 European Medicines Agency
3.3.2 Biomarkers Qualified by the Fda
Chapter 4 Impact of Covid-19 Pandemic
4.1 Impact of Covid-19 on Renal Biomarker Market
4.1.1 Increased Incidence of Aki
4.1.2 Other Diseases
4.2 Chronic Dialysis Patients
4.2.1 Kidney Transplant Recipients
Chapter 5 Global Renal Biomarker Market by Type
5.1 Overview
5.2 Filtered Renal Biomarkers (Impaired Tubular Reabsorption)
5.2.1 Albumin
5.2.2 Cystatin C
5.2.3 Beta-2 Microglobulin
5.3 Upregulated Biomarkers
5.3.1 Kim-1 Kidney Injury Molecule
5.3.2 Neutrophil Gelatinase Associated Lipocalin
5.3.3 Clusterin
5.3.4 Interleukin-18
5.3.5 Netrin-1
5.4 Preformed
5.4.1 Alkaline Phosphatase
5.4.2 Gamma-Glutamyl Transpeptidase
5.4.3 Glutathione S-Transferase
5.4.4 N-Acetyl-b-D Glucosaminidase
5.4.5 Liver-Type Fatty Acid-Binding Protein
5.4.6 Tissue Inhibitor of Metalloprotease-2 and Insulin-Like Growth Factor-Binding Protein 7
5.5 Other Biomarkers
5.5.1 Blood Urea Nitrogen
5.5.2 Serum Creatinine
5.5.3 Downregulated
Chapter 6 Global Market for Renal Biomarkers by Region
6.1 North America
6.1.1 United States
6.1.2 Canada
6.2 Europe
6.2.1 Germany
6.2.2 Italy
6.2.3 France
6.2.4 Spain
6.2.5 United Kingdom
6.2.6 Rest of Europe
6.3 Asia-Pacific
6.3.1 Australia
6.3.2 Japan
6.3.3 China
6.3.4 Rest of Asia
6.4 Rest of the World
Chapter 7 Renal Biomarker Market by End-user
7.1 Hospitals
7.2 Research Centers
7.3 Other End-users
Chapter 8 Renal Biomarker Market by Technique
8.1 Overview
8.2 Enzyme Linked Immunosorbent Assay
8.3 Particle-Enhanced Turbidimetric Immunoassays
8.4 Colorimetric Assays
8.5 Chemiluminescent Enzyme Immunoassays
8.6 Other Detection Methods
Chapter 9 Competitive Landscape
Chapter 10 Company Profiles
Abbott Laboratories
Beckman Coulter Inc.
Biomerieux
Bioporto A/S
Bio-Rad
Enzo Biochem Inc.
Gentian Diagnostic Ab
Hytest Ltd.
Nephrosant
Nexelis
Proteomics International Laboratories Ltd.
Randox Laboratories Ltd.
Roche (F. Hoffmann-La Roche Ag)
Sphingotec
Thermo Fisher Scientific
Chapter 11 Patent Review
Chapter 12 Clinical Trial Analysis
For more information about this report visit https://www.researchandmarkets.com/r/ranp91
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/renal-biomarkers-technologies-and-global-report-2022-market-data-and-projections-2019-2027-featuring-biomerieux-gentian-diagnostic-proteomics-thermo-fisher-scientific-sphingotec-and-bioporto-301713427.html
SOURCE Research and Markets
Roku today is expanding its product line to include a range of smart TVs that are the first to be both designed and built by Roku itself. The Roku Select and Roku Plus Series TVs will be Roku-branded HD and 4K TVs available across 11 models, ranging from 24” to 75” in size, and made to work well with Roku's growing line of audio products, like its Roku TV Wireless Soundbar, as well as other Roku accessories, like its Voice Remote. All of Roku's new HD TVs will include the Roku Voice Remote, while the Plus models will come with the higher-end Roku Voice Remote Pro.
The memory giant rose on reports that China may be throwing in the towel on subsidizing competitors.
The On-Balance-Volume (OBV) line shows some slight improvement from late September. The Moving Average Convergence Divergence (MACD) oscillator is bullish. The weekly OBV line has stayed steady but the MACD oscillator is now above the zero line and bullish.
In early 2021, Apple turned the digital advertising world on its head. This put a multibillion-dollar dent in the online advertising last year, disrupting companies including Alphabet's (NASDAQ: GOOGL) (NASDAQ: GOOG) Google and Facebook parent Meta Platforms (NASDAQ: META), which rely exclusively on targeted ads for the lion's share of their revenue.
Buffett's company, Berkshire Hathaway, is much more invested in the tech sector than it used to be.
The oncology company's stock has been correcting sideways for a few months but seems poised for renewed gains.
ExxonMobil (NYSE: XOM) is starting to feel the pinch of lower oil prices. The oil giant's profits could continue declining in 2023 if oil and gas prices don't perk back up. The company's profit slump might have investors wondering if it's time to sell.
Apple is facing an uphill battle as it plans to shift its production out of China. Here’s why it’s difficult to replicate Foxconn’s ‘iPhone City’ in Zhengzhou and the company’s finely-tuned ecosystem in countries like India and Vietnam. Photo: Karen Dias/Bloomberg News
Shares of Unity Software (NYSE: U) dropped 27.6% in December, according to data provided by S&P Global Market Intelligence. The S&P 500 was down nearly 6%, so these market conditions certainly helped nudge Unity stock downwards. On Dec. 8, BTIG analyst Clark Lampen downgraded Unity stock to a neutral rating from a buy rating, according to The Fly.
Yahoo Finance tech reporter Allie Garfinkle reports live from the 2023 CES Tech Conference on the latest innovations that have been unveiled.
Employers are increasingly relying on skills rather than experience and degrees as the key filter through which to evaluate candidates on LinkedIn.
‘If a relationship did not work out, I would have a big problem parting with any of my pension or savings.’
JPMorgan Chase & Co was ordered by a New York judge to face a lawsuit by the French maker of Ray-Ban sunglasses, which said cybercriminals withdrew $272 million from its New York account after the bank ignored "red flags" of suspicious activity. U.S. District Judge Lewis Liman on Wednesday ruled that a Thailand unit of EssilorLuxottica SA can try to prove that JPMorgan violated a New York law governing commercial contracts that requires refunds of unauthorized payment orders. Essilor said warning signs of fraud included transfers being made in whole-dollar amounts and through small banks going to unfamiliar entities associated with coffee, furniture and hair care instead of the optical industry.
In this article, we discuss the 10 biggest nickel mining companies in the world. To skip the industry analysis, you can go directly to the 5 Biggest Nickel Mining Companies in the World. Nickel production started globally in 1824 through cobalt blue production while the first large-scale production began in 1848 in Norway. The demand […]
GE HealthCare is now set to make its own moves.
Salesforce, the San Francisco-based customer management software company, announced Wednesday it will cut 10% of its 80,000-strong global workforce and exit office leases. Here's the letter to employees co-CEO Marc Benioff sent explaining the reasoning behind the cuts: As one ‘Ohana, over the last 23 years, Salesforce has built the #1 CRM that drives incredible customer success across every line of business for every industry around the world.
The company unveiled new technology for more precise farming—and an electric excavator for construction sites.
Chinese automakers can build an electric vehicle (EV) for 10,000 euros ($10,618) less than European automakers, an overwhelming cost advantage that will put pressure on European manufacturers in their home market, the head of auto supplier Forvia said. As European consumers seek cheap EVs, Forvia Chief Executive Patrick Koller told the CES convention in Las Vegas on Wednesday that China was producing "good vehicles" and Europe would not be able to stop imports. The issue is "more dangerous" for Europe than the United States, Koller told Reuters in an interview, as high duties have limited China's U.S. market share.
A Roth Individual Retirement Account (IRA) can offer tax benefits in the form of tax-free withdrawals in retirement. If you have a traditional IRA or 401(k), you can use a Roth conversion to change the tax status of your retirement … Continue reading → The post How Many Roth Conversions Can You Make Per Year? appeared first on SmartAsset Blog.
The $1 billion transaction has also been opposed by the Securities and Exchange Commission and Texas regulators